Objective To estimate the magnitude of the correlation between neonatal outcomes of twins and demonstrate how this information can be used in the design of randomised controlled trials (RCTs) in women with twin pregnancies.
Introduction
Twin births and their associated complications are on the rise. In high-income countries, twin births now account for around 2-4% of all births due to increasing use of assisted reproductive technologies and advancing maternal age. 1 Compared with singleton pregnancies, twins have a higher risk of adverse neonatal outcomes including preterm birth, respiratory distress syndrome, low birthweight, and mortality. 2, 3 Antenatal interventions intended to improve neonatal outcomes, such as prophylactic progesterone treatment, have been studied specifically in women with twin pregnancies but with limited success. [4] [5] [6] [7] [8] [9] Further randomised controlled trials (RCTs) evaluating promising interventions in this high-risk population are needed.
Designing and analysing RCTs in women with twin pregnancies is challenging. Twins born to the same mother are expected to have similar or correlated outcomes due to the shared fetal and neonatal environment and common genetic material. 10, 11 As a result, infants born from the same twin pregnancy cannot be viewed as two independent trial participants and this has implications for the trial design and analysis. In particular, the correlation between outcomes of twins should be taken into account in the sample size calculations to maintain the desired power, 12 and in the analysis to avoid producing results that are over-precise. 13 The higher the correlation, the larger the impact twins have on the sample size and analysis.
An accurate estimate of the correlation between twins is important, as this is likely to vary across different outcomes and populations. Higher correlation is expected for certain outcomes, such as gestational age at birth, where the twin-to-twin delivery interval rarely exceeds 1 day. Higher correlation is also expected in certain populations, such as monochorionic twin pregnancies, where twins share both their genetics and placenta. An estimate of the relevant correlation from an external source is often required. As the correlation between neonatal outcomes of twins is rarely reported in trial publications, 14 appropriately designing and analysing RCTs in women with twin pregnancies can be difficult and published estimates are needed.
The purpose of this study was to estimate the magnitude of the correlation between neonatal outcomes of twins for commonly reported outcomes, both overall and by chorionicity. We demonstrate how this information can be used in sample size calculations for RCTs in women with twin pregnancies, as this is likely to be their most common use, and discuss other potential uses in Bayesian analyses and meta-analyses.
Methods

Data sets
Twelve data sets including a total of 4504 twin pairs were used to estimate intraclass correlation coefficients (ICCs), as summarised in Tables S1 and S2 . The data sets were from a convenience sample of RCTs chosen based on the availability of individual participant data for twins with adverse neonatal outcomes defined in a standardised manner as part of previous studies. The principal investigators of all RCTs were contacted and provided permission to use the data for this study. The first data set comes from a multicentre, open-label RCT assessing the effectiveness of a cervical pessary compared with no intervention for preventing poor perinatal outcomes. 15 The trial recruited 813 women with a multiple pregnancy between 12 and 20 weeks of gestation, of whom 795 had a twin pregnancy (23% monochorionic, 77% dichorionic) and were part of this study. Exclusion criteria were known serious congenital defects, fetal death, twin-to-twin transfusion syndrome, and known placenta praevia. Women assigned to the cervical pessary group had a pessary inserted between 16 and 20 weeks of gestation and removed in the 36th week of gestation; women in the control group received standard antenatal care. Approximately 55% of women delivered preterm (less than 37 weeks of gestation).
The remaining data sets come from 11 RCTs included in an individual participant data meta-analysis designed to investigate the effects of progestogens in women with a twin pregnancy. 16 Trials were eligible for inclusion if they compared the effect of vaginally administered progesterone or intramuscular 17-hydroxyprogesterone caproate (17Pc) versus placebo or non-intervention in the second or third trimester in women with a twin pregnancy on either preterm birth or adverse perinatal outcome. Thirteen trials met the inclusion criteria and contributed individual participant data to the meta-analysis; however, only the 11 trials that included a minimum of 40 women with a twin pregnancy were included in this study. [4] [5] [6] [7] [8] [9] [17] [18] [19] [20] [21] Inclusion/exclusion criteria and treatment regimens varied between these trials (Table S1 ). The study size ranged from 67 to 677 twin pairs, with trials either including both monochorionic and dichorionic twin pregnancies, 4, 5, 7, 17, 18, 21 dichorionic twin pregnancies only 6, 8, 19 or not recording chorionicity 9, 20 (Table S2 ). Preterm birth rates (<37 weeks of gestation) ranged from 50 to 79%.
Neonatal outcomes
For each trial, the following 12 neonatal outcomes were defined where possible: perinatal death (intrauterine fetal death at any gestational age or neonatal death before hospital discharge); respiratory distress syndrome (RDS) requiring oxygen for at least 24 hours; bronchopulmonary dysplasia (BPD); intraventricular haemorrhage (IVH) grade III or IV; necrotising enterocolitis (NEC) grade II or higher; culture-proven sepsis; admission to the neonatal intensive care unit (NICU); birthweight; low birthweight (<2500 g and <1500 g); and two composite measures of adverse neonatal outcome, as defined in a previous study. 16 The first composite outcome included perinatal death, RDS, BPD, IVH, NEC, and sepsis, and the second included perinatal death, RDS, IVH, and NEC.
Statistical methods
The magnitude of the correlation between neonatal outcomes of twins was measured using the ICC. An ICC of 0 indicates that neonatal outcomes of twins are completely independent and the ICC approaches 1 for neonatal outcomes typically experienced by either both or neither member of a twin pair. The data were analysed using log-binomial models for binary outcomes and linear models for continuous outcomes. Adjustment was made for treatment group, as ICCs calculated ignoring potential treatment effects may be biased, 22 and a single ICC was estimated for both treatment groups combined. Clustering due to twins was taken into account using generalised estimating equations (GEEs), as this is the most common analysis approach used to account for twins in RCTs. 14, 23 ICCs were estimated by the correlation parameter for the exchangeable working correlation structure; more complex correlation structures reduce to an exchangeable correlation structure when the cluster size is two. As a sensitivity analysis, ICCs were also estimated from linear mixedeffects models with a random mother effect. Confidence intervals (CIs) for ICCs were obtained via bootstrapping using the bias-corrected and accelerated method 24 with 2000 bootstrap samples and resampling of clusters (mothers), rather than individuals (infants). Each trial was analysed separately, both overall and by chorionicity where available. No analysis was performed for individual outcomes in trials where there were less than 40 sets of twins with available data for the outcome, or less than 10 cases of a binary outcome, as the ICC estimates were considered too unreliable and GEEs are known to produce biased residuals when the number of clusters is small. 25, 26 ICCs and 95% CIs are presented by trial, along with the prevalence for binary outcomes and the mean and standard deviation (SD) for continuous outcomes. ICC estimates are summarised descriptively across trials by the median and range; no meta-analysis was performed. ICCs were calculated for the components of the composite outcomes for completeness; however, only summary information is presented for these outcomes, as they are relatively rare and hence are unlikely to be chosen as the primary outcome for a future trial. Analyses were performed using SAS v9.4 (Cary, NC, USA) based on the %BOOT and % BOOTCI macros. 27 Results Table 1 for each outcome and trial were above 0.5, indicating a moderate to strong correlation between adverse neonatal outcomes of twins. ICC estimates were generally fairly consistent across trials, despite considerable variation in outcome prevalence and differences in inclusion/exclusion criteria between trials. Chorionicity had no clear effect on ICC estimates, which were mostly similar for infants from monochorionic and dichorionic twin pregnancies (Tables  S3-S8 ). Mixed-effects models generally produced similar ICC estimates (Table S9) .
Example sample size calculation
To illustrate how the ICCs presented in this article can be used in sample size calculations for future RCTs in women with twin pregnancies, we present the following hypothetical example. Suppose a multicentre RCT is planned to assess the effect of a promising new drug for women with a twin pregnancy on adverse neonatal outcomes. Women with a monochorionic or dichorionic twin pregnancy diagnosed by ultrasound will be randomised at between 16 and 20 weeks of gestation to receive the new drug or placebo in a ratio of 1:1. The primary outcome for the trial is a composite neonatal outcome of perinatal death, RDS, BPD, IVH, NEC, and sepsis. The outcome prevalence in the control group is expected to be 15%, and the trial investigators believe the new drug will reduce the prevalence by at least 40%. Two steps are involved in calculating the sample size for RCTs in women with twin pregnancies. First, the sample size is calculated using standard methods assuming outcomes of infants from a twin pregnancy are independent. If the proposed trial were conducted under this assumption, a total of 986 infants (493 per group) would be required to detect a 40% reduction in the risk of adverse neonatal outcome from 15 to 9%, based on a continuity-corrected Chisquare test with two-sided a = 0.05 and 80% power. Secondly, the sample size is multiplied by a quantity known as the design effect, which is given by 1 + ICC for trials randomising and treating pregnant women and only including twin pregnancies. 28 The ICC estimates presented in this article can be used to calculate this design effect and hence the final sample size. The median ICC for the primary outcome of the proposed trial across previous similar trials is 0.68 (Table 1) , which produces a design effect of 1.68 and increases the sample size for the proposed trial to a total of 1.68 9 986 = 1658 twin infants (after rounding up to the next even number), or 829 women with a twin pregnancy. Power calculations can be performed to examine the impact on power if the ICC is at the upper end of the range of likely values. For the proposed trial, the sample size of 1658 infants based on an ICC of 0.68 would provide 79% or 75% power if the ICC turned out to be 0.71 or 0.88, respectively, corresponding to the maximum values for the ICC estimate and the upper limit of the 95% confidence interval for the ICC estimate observed across similar trials (Table S3) .
Discussion
Main findings
We present estimates of the correlation between outcomes of twins for a range of commonly reported neonatal outcomes using data from 12 RCTs randomising women with twin pregnancies. ICCs were generally above 0.5, indicating moderate to strong correlation between neonatal outcomes of twins, and were generally similar to chorionicity. ICCs were also fairly consistent across trials, despite differences in outcome prevalence and inclusion/exclusion criteria. However, there was considerable variability in ICCs between outcomes and some ICCs were lower than might be expected for twins. Our example sample size calculation illustrates how these ICCs can be used in the design of RCTs in women with twin pregnancies and the large impact that twins can have on the sample size.
Strengths and limitations
The key strength of this study is that, to our knowledge, it provides the first comprehensive report of ICCs for neonatal outcomes in twins. These ICCs will inform the design and analysis of future RCTs and systematic reviews evaluating interventions designed to improve neonatal outcomes in women with twin pregnancies. Another strength is the use of data from multiple RCTs to provide multiple estimates of the ICC for each outcome. This provides researchers with a range of likely ICC values for each neonatal outcome of interest.
A limitation of this study is that the ICCs were estimated from RCTs chosen for convenience, the vast majority of which investigated the effect of progestogens on neonatal outcomes, and may not be representative of all RCTs in women with twin pregnancies. Additional ICC estimates are needed from other RCTs and epidemiological studies involving twin pregnancies that focus on different clinical conditions and employ varying inclusion/exclusion criteria to obtain a more complete picture of the dependence between neonatal outcomes that occurs in twins. A further limitation is that we did not investigate the degree of outcome concordance within twin pairs that is beyond chance; this is an interesting area for further research.
Interpretation
External estimates of ICCs for neonatal outcomes in twins, such as those presented in this article, can be used by researchers in several settings. The most common use is likely to be in designing RCTs in women with twin pregnancies, where it is important to account for the dependence between neonatal outcomes of twins in sample size calculations to ensure the trial is adequately powered to answer the primary research question. This can be achieved by simply calculating the sample size using standard methods assuming outcomes of all infants are independent and then multiplying by a design effect of 1 + ICC. 28 Our example sample size calculation illustrates this process using the median ICC across trials, although in practice it may be sensible to use the ICC estimate from the most similar trial in terms of inclusion/exclusion criteria. Alternatively, an ICC estimate may be obtained from a pilot study, although this requires resources that may not be available and is likely to yield a very imprecise ICC estimate. Our ICC estimates were generally above 0.5, indicating that RCTs focusing on twins are likely to require at least 50% more infants than are RCTs focusing on singletons, and that failure to account for twins in the sample size calculation could result in a trial with much lower than expected power. However, this does not necessarily mean that appropriately powered RCTs in twins will be more expensive than trials in singletons, as the costs associated with recruiting mothers and collecting mother level information are halved for twins. Many RCTs allow women with either a singleton or twin pregnancy to participate, and our ICC estimates can also be used to calculate the sample size for these trials by incorporating the twin pregnancy rate in the target population into the calculation of the design effect. 28 Another likely use of external ICC estimates is in the analysis of RCTs including women with twin pregnancies. Previous studies have investigated the performance of different statistical methods for analysing neonatal outcomes in twins and recommended using an approach that takes the correlation between outcomes of twins into account, such as GEEs or mixed-effects models. 10, 11, [29] [30] [31] [32] If a trial is too small or includes too few women with a multiple pregnancy to provide a precise estimate of the ICC in the analysis, it may be preferable to use an external estimate. The Bayesian framework provides a formal method of incorporating external evidence into the analysis by specifying an informative prior for the ICC. 33 This has the advantage of utilising the uncertainty around the ICC estimate as well as the point value and may be the most appropriate way to use the external information.
The final anticipated use of external ICC estimates is in systematic reviews and meta-analyses involving RCTs that include women with twin pregnancies. Adjustment of standard errors or sample size is common in meta-analyses of outcomes collected in cluster RCTs 34 but this approach is rarely applied to outcomes of infants from multiple pregnancies. By providing estimates of ICCs for neonatal outcomes in twins, we hope to encourage researchers to perform similar adjustments for meta-analyses including RCTs that recruited women with twin pregnancies. Such adjustments can appropriately increase the uncertainty around the treatment effect estimates and help guard against overly optimistic conclusions regarding the effectiveness of the intervention.
As expected, we found considerable variability in ICCs between neonatal outcomes. This variability may be due to differences in outcome prevalence, as well as the nature of the outcome. Median ICC estimates were as low as 0.13, which is substantially lower than we had anticipated for neonatal outcomes of twins. As this median was based on only two trials with sufficient data to estimate the ICC for NEC, this finding should be interpreted with some caution. The next lowest median ICC estimates observed were 0.36 for IVH and 0.38 for sepsis, which are also somewhat lower than anticipated. We also expected ICCs to be higher for monochorionic than for dichorionic twins due to the shared placenta; however, chorionicity had no clear effect on ICC estimates. This could be due to the relatively small sample sizes available in these subgroups, as reflected in the wide confidence intervals for the ICCs, or unequal placental sharing in monochorionic twins. Alternatively, it may be due to the choice of neonatal outcomes studied, many of which are imprecise measures of the underlying clinical state. Further investigation of the impact of chorionicity on ICCs using data from larger epidemiological studies would be useful in informing the design and analysis of future RCTs specifically recruiting women with monochorionic or dichorionic twin pregnancies.
Conclusion
The correlation between neonatal outcomes of twins varies considerably between outcomes. It is generally moderate to high but may be lower than expected for some outcomes. This highlights the importance of obtaining an accurate estimate of the ICC for the relevant outcome and population to use in the design and analysis of RCTs that recruit women with twin pregnancies. Our ICC estimates will be useful to researchers requiring external information on these parameters for calculating the sample size, performing Bayesian analyses, and adjusting meta-analyses to account for twins. Future RCTs including women with twin pregnancies should make use of these and other suitable ICC estimates during the trial design phase to ensure they are adequately powered to answer the primary research question. Researchers are encouraged to report ICCs for neonatal outcomes in twins in their own trials to add to the growing body of published ICCs.
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